Molecular aspects and gene therapy prospects for diastolic failure

Keith A Webster, Nanette Bishopric

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Because of safety issues, components of the β-adrenergic signaling pathway cannot currently be viewed as attractive targets for human gene therapy. Rather, the balance of evidence supports strategies that will target gene products specifically and directly at diastolic regulation. Augmenting the activity of the SR Ca2+ ATPase by AAV-mediated delivery of the SERCA2a gene, directed by a cardiac-specific promoter with a tightly regulable on-off switch is perhaps the most attractive strategy. PLB and cTnI also are attractive targets but only if molecular techniques can be devised to modulate their activity specifically and conditionally. Such techniques may involve modifying the phosphorylation sites in vitro and replacing wild type proteins in the failing heart with the modified forms, again using regulated AAV vectors for gene delivery.

Original languageEnglish
Pages (from-to)621-635
Number of pages15
JournalCardiology Clinics
Volume18
Issue number3
StatePublished - Sep 19 2000

Fingerprint

Genetic Therapy
Genes
Calcium-Transporting ATPases
Adrenergic Agents
Phosphorylation
Safety
Proteins
In Vitro Techniques

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Webster, K. A., & Bishopric, N. (2000). Molecular aspects and gene therapy prospects for diastolic failure. Cardiology Clinics, 18(3), 621-635.

Molecular aspects and gene therapy prospects for diastolic failure. / Webster, Keith A; Bishopric, Nanette.

In: Cardiology Clinics, Vol. 18, No. 3, 19.09.2000, p. 621-635.

Research output: Contribution to journalArticle

Webster, KA & Bishopric, N 2000, 'Molecular aspects and gene therapy prospects for diastolic failure', Cardiology Clinics, vol. 18, no. 3, pp. 621-635.
Webster, Keith A ; Bishopric, Nanette. / Molecular aspects and gene therapy prospects for diastolic failure. In: Cardiology Clinics. 2000 ; Vol. 18, No. 3. pp. 621-635.
@article{265e92e43c0c42f79885eaa3715b835d,
title = "Molecular aspects and gene therapy prospects for diastolic failure",
abstract = "Because of safety issues, components of the β-adrenergic signaling pathway cannot currently be viewed as attractive targets for human gene therapy. Rather, the balance of evidence supports strategies that will target gene products specifically and directly at diastolic regulation. Augmenting the activity of the SR Ca2+ ATPase by AAV-mediated delivery of the SERCA2a gene, directed by a cardiac-specific promoter with a tightly regulable on-off switch is perhaps the most attractive strategy. PLB and cTnI also are attractive targets but only if molecular techniques can be devised to modulate their activity specifically and conditionally. Such techniques may involve modifying the phosphorylation sites in vitro and replacing wild type proteins in the failing heart with the modified forms, again using regulated AAV vectors for gene delivery.",
author = "Webster, {Keith A} and Nanette Bishopric",
year = "2000",
month = "9",
day = "19",
language = "English",
volume = "18",
pages = "621--635",
journal = "Cardiology Clinics",
issn = "0733-8651",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Molecular aspects and gene therapy prospects for diastolic failure

AU - Webster, Keith A

AU - Bishopric, Nanette

PY - 2000/9/19

Y1 - 2000/9/19

N2 - Because of safety issues, components of the β-adrenergic signaling pathway cannot currently be viewed as attractive targets for human gene therapy. Rather, the balance of evidence supports strategies that will target gene products specifically and directly at diastolic regulation. Augmenting the activity of the SR Ca2+ ATPase by AAV-mediated delivery of the SERCA2a gene, directed by a cardiac-specific promoter with a tightly regulable on-off switch is perhaps the most attractive strategy. PLB and cTnI also are attractive targets but only if molecular techniques can be devised to modulate their activity specifically and conditionally. Such techniques may involve modifying the phosphorylation sites in vitro and replacing wild type proteins in the failing heart with the modified forms, again using regulated AAV vectors for gene delivery.

AB - Because of safety issues, components of the β-adrenergic signaling pathway cannot currently be viewed as attractive targets for human gene therapy. Rather, the balance of evidence supports strategies that will target gene products specifically and directly at diastolic regulation. Augmenting the activity of the SR Ca2+ ATPase by AAV-mediated delivery of the SERCA2a gene, directed by a cardiac-specific promoter with a tightly regulable on-off switch is perhaps the most attractive strategy. PLB and cTnI also are attractive targets but only if molecular techniques can be devised to modulate their activity specifically and conditionally. Such techniques may involve modifying the phosphorylation sites in vitro and replacing wild type proteins in the failing heart with the modified forms, again using regulated AAV vectors for gene delivery.

UR - http://www.scopus.com/inward/record.url?scp=0033864376&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033864376&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 621

EP - 635

JO - Cardiology Clinics

JF - Cardiology Clinics

SN - 0733-8651

IS - 3

ER -